Literature DB >> 8475557

Probable antibody-mediated failure of two sequential ABO-compatible hepatic allografts in a single recipient.

L E Ratner1, D Phelan, E M Brunt, T Mohanakumar, D W Hanto.   

Abstract

Two sequential ABO-compatible orthotopic liver allografts failed, despite excellent initial posttransplant function, in a patient with preformed donor-specific alloantibodies. There was no evidence of cell-mediated rejection. Retrospective crossmatching of recipient serum, obtained immediately prior to the first transplant, revealed the presence of lymphocytotoxic antibodies directed against donor class I HLA B17, at a titer of greater than 1:32,768. Similarly, lymphocytotoxic antibodies directed against the second donor's class I HLA A2 phenotype were detected on retrospective crossmatching utilizing both the three-wash Amos technique (TWA-CDC), and the anti-human immunoglobulin augmented technique (AHG-CDC), at a titer of greater than 1:32,768. Anti-class I specific alloantibodies were eluted from both failed liver grafts at titers of 1:256. The hepatic necrosis in zones 3 and 2 that were observed on histologic examination, and the profound refractory consumptive thrombocytopenia subsequent to each transplant may have been the result of antibody-mediated rejection by preformed lymphocytotoxic antibodies. Despite the liver's remarkable capacity to withstand antibody-mediated injury, primary humoral rejection following ABO compatible liver transplantation may occur if extremely high titers of performed allospecific lymphocytotoxic antibodies are present.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8475557     DOI: 10.1097/00007890-199304000-00025

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  6 in total

1.  Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch.

Authors:  H R Doyle; I R Marino; F Morelli; C Doria; L Aldrighetti; J McMichael; J Martell; T Gayowski; T E Starzl
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

2.  The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation.

Authors:  A I Musat; R M Agni; P Y Wai; J D Pirsch; D F Lorentzen; A Powell; G E Leverson; J M Bellingham; L A Fernandez; D P Foley; J D Mezrich; A M D'Alessandro; M R Lucey
Journal:  Am J Transplant       Date:  2011-03       Impact factor: 8.086

3.  Bortezomib for acute antibody-mediated rejection in liver transplantation.

Authors:  F Paterno; M Shiller; G Tillery; J G O'Leary; B Susskind; J Trotter; G B Klintmalm
Journal:  Am J Transplant       Date:  2012-06-08       Impact factor: 8.086

4.  Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation.

Authors:  Nassim Kamar; Laurence Lavayssière; Fabrice Muscari; Janick Selves; Céline Guilbeau-Frugier; Isabelle Cardeau; Laure Esposito; Olivier Cointault; Marie Béatrice Nogier; Jean Marie Peron; Philippe Otal; Marylise Fort; Lionel Rostaing
Journal:  World J Gastroenterol       Date:  2009-07-21       Impact factor: 5.742

5.  Antibody-mediated rejection after adult living-donor liver transplantation triggered by positive lymphocyte cross-match combination.

Authors:  Tomohide Hori; Hiroto Egawa; Shinji Uemoto
Journal:  Ann Gastroenterol       Date:  2012

6.  Acute liver failure secondary to acute antibody mediated rejection after compatible liver transplant: A case report.

Authors:  Todd J Robinson; James B Hendele; Idoia Gimferrer; Nicolae Leca; Scott W Biggins; Jorge D Reyes; Lena Sibulesky
Journal:  World J Hepatol       Date:  2022-01-27
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.